Literature DB >> 1632663

Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis.

H J Haga1, D D'Cruz, R Asherson, G R Hughes.   

Abstract

A predominantly outpatient regimen of low dose intravenous cyclophosphamide was used to treat patients with serious progressive connective tissue diseases. Fifty five patients were treated with a total of 211 intravenous pulses of cyclophosphamide. Forty five patients had previously shown no response to a variety of other treatments. Low dose intravenous cyclophosphamide (500 mg) was given in 179 pulses and repeated pulses were given in most patients at weekly intervals for one to three weeks to induce disease remission. A good response was noted in 37 of 55 (67%) patients assessed four weeks after the pulses. Only 20 patients needed more than one such course of three pulses of intravenous cyclophosphamide during the observation period. The non-responders were characterised by longstanding disease and irreversible histological findings in renal and muscle biopsy samples. Patients with vasculitis, notably Wegener's granulomatosis, showed the most immediate response, and in most patients the amount of corticosteroids required was markedly reduced. In some patients steroids were completely stopped during the follow up period. The most striking observation of this effective but more conservative regimen was the low incidence of major side effects such as neutropenia and infections. It is concluded that low dose pulses of intravenous cyclophosphamide are well tolerated and are an effective treatment for patients with aggressive connective tissue diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632663      PMCID: PMC1004774          DOI: 10.1136/ard.51.7.885

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Corticosteroids and infections.

Authors:  E H KASS; M FINLAND
Journal:  Adv Intern Med       Date:  1958

2.  Cyclophosphamide in severe polymyositis.

Authors:  S Bombardieri; G R Hughes; R Neri; P Del Bravo; L Del Bono
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

3.  Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma.

Authors:  J Pedersen-Bjergaard; J Ersbøll; V L Hansen; B L Sørensen; K Christoffersen; K Hou-Jensen; N I Nissen; J B Knudsen; M M Hansen
Journal:  N Engl J Med       Date:  1988-04-21       Impact factor: 91.245

Review 4.  Cytotoxic drugs: their clinical application to the rheumatic diseases.

Authors:  P J Clements; J Davis
Journal:  Semin Arthritis Rheum       Date:  1986-05       Impact factor: 5.532

Review 5.  Adrenal glucocorticoids after twenty years. A review of their clinically relevant consequences.

Authors:  D S David; M H Grieco; P Cushman
Journal:  J Chronic Dis       Date:  1970-03

6.  Infectious complications of cyclophosphamide treatment for vasculitis.

Authors:  J D Bradley; K D Brandt; B P Katz
Journal:  Arthritis Rheum       Date:  1989-01

7.  Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study.

Authors:  F A Houssiau; D P D'Cruz; H J Haga; G R Hughes
Journal:  Lupus       Date:  1991-11       Impact factor: 2.911

8.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

Authors:  H A Austin; J H Klippel; J E Balow; N G le Riche; A D Steinberg; P H Plotz; J L Decker
Journal:  N Engl J Med       Date:  1986-03-06       Impact factor: 91.245

9.  Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.

Authors:  W J McCune; J Golbus; W Zeldes; P Bohlke; R Dunne; D A Fox
Journal:  N Engl J Med       Date:  1988-06-02       Impact factor: 91.245

10.  Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

Authors:  H L Currey; J Harris; R M Mason; J Woodland; T Beveridge; C J Roberts; D W Vere; A S Dixon; J Davies; B Owen-Smith
Journal:  Br Med J       Date:  1974-09-28
View more
  12 in total

1.  The treatment of Wegener's granulomatosis.

Authors:  R A DeRemee
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

2.  Vasculitides throughout history and their clinical treatment today.

Authors:  Antonio Iglesias-Gamarra; Edgar Penaranda; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

Review 3.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

4.  Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide.

Authors:  I Martin-Suarez; D D'Cruz; M Mansoor; A P Fernandes; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

Review 5.  Lupus therapy.

Authors:  H Baart de la Faille
Journal:  Clin Investig       Date:  1994-10

6.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

7.  Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study.

Authors:  Salvatore D'Angelo; Giovanna Cuomo; Carmen Paone; Emiliana Colutta; Giovanni La Montagna; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2003-10-23       Impact factor: 2.980

8.  Intravenous pulse cyclophosphamide--a new regime for steroid-resistant minimal change nephrotic syndrome.

Authors:  R Elhence; S Gulati; V Kher; A Gupta; R K Sharma
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

9.  Pregnancy in granulomatous vasculitis.

Authors:  F Lima; N Buchanan; L Froes; S Kerslake; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

10.  Inflammatory Myopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.